Tofacitinib in paediatric dermatoses: a narrative review.
Clin Exp Dermatol
; 47(7): 1256-1264, 2022 Jul.
Article
in English
| MEDLINE | ID: covidwho-1968075
ABSTRACT
Tofacitinib has revolutionized the treatment of numerous dermatological conditions in different age groups. However, evidence for its effectiveness, safety and tolerability in the paediatric population is limited. We performed a literature search, which showed that oral tofacitinib is a reliable option in refractory juvenile dermatomyositis, severe alopecia areata, atopic dermatitis and psoriasis. Topical tofacitinib is an effective option in vitiligo and halo naevus. The risk-benefit ratio should be assessed prior to consideration of this molecule. In this narrative review, we have attempted to present a summary of the evidence of using tofacitinib (oral and topical) in paediatric dermatoses.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pyrroles
/
Alopecia Areata
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Child
/
Humans
Language:
English
Journal:
Clin Exp Dermatol
Year:
2022
Document Type:
Article
Affiliation country:
Ced.15175
Similar
MEDLINE
...
LILACS
LIS